Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir
Treatment for Acute Hepatitis C
Typical Dosage: Two O/P/R tablets once daily + one Dasabuvir tablet twice daily
Effectiveness
96%
Safety Score
65%
Clinical Trials
1
Participants
5K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
65
DangerousModerateSafe
Treatment Details
Dosage Range
Two O/P/R tablets once daily + one Dasabuvir tablet twice daily
Time to Effect
Within 12 weeks of treatment completion
Treatment Duration
12 weeks
Evidence Quality
HIGHNumber Needed to Treat (NNT)
1(Treat 1 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
50(Treat 50 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$22,000
Monitoring:$1,200
Side Effect Mgmt:$300
Total Annual:$23,500
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$80,000/QALY
QALYs Gained
2.7
Outcome-Based Costs
Cost per Responder
$24,479
Cost per Remission
$24,479
Comparison vs Pegylated Interferon + Ribavirin
Cost Difference
$-11,500/year
Less expensive
QALY Difference
+2.20 QALYs
Better outcomes
Dominance
DOMINATESBetter + cheaper
Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir Outcomes
for Acute Hepatitis C
Efficacy Outcomes
Overall Effectiveness
+96%
Response Rate
+96%
Remission Rate
+96%
Common Side Effects
Fatigue
+21%
Nausea
+11%
Insomnia
+9%
Pruritus
+6%
Elevated liver enzymes
+4%
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov
Completed Clinical Trials
1 completed trial for Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir in Acute Hepatitis C
Treatment of Recently Acquired Hepatitis C With the 3D Regimen or G/P
NCT02634008COMPLETEDPHASE3
83 participants
INTERVENTIONAL
Sydney, Australia +10 more
Started: Jun 1, 2016